Barclays analyst Carter Gould maintained a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $3.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback